Lupin gets US nod for copy of oral contraceptive Yasmin

Pharma major Lupin  has received final US Food and Drug Administration approval for its Drospirenone and Ethinyl Estradiol Tablets in 3mg/0.03mg strength.  Lupin can now market the drug, which is a generic version of Bayer Healthcare's Yasmin tablets.

The Drospirenone and Ethinyl Estradiol Tablets are a combined oral contraceptive indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Lupin said it will market the tablets in a wallet pack of 28 tablets consisting of 21 yellow active tablets, each containing 3 mg Drospirenone and 0.03 mg Ethinyl Estradiol, and 7 white inert tablets.

Yasmin tablets had annual sales of about USD 275 million in the US market, it said, citing IMS Health data for September 2012.

Lupin shares closed up over 1 percent at Rs 616.85 on NSE on Wednesday.